{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-401157","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2026-09-24T21:11:07+00:00","discovered_at":"2026-09-24T21:12:00.438040+00:00","generated_at":"2026-09-24T21:12:06.441903+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Acadia Phase 2 RADIANT: remlifanserin 60mg misses primary endpoint (p=0.0603) but supports Phase 3","bullets":["Primary SAPS-H+D: 60mg change -12.6 vs placebo -10.4 (week 6), effect size 0.26, p=0.0603.","Key secondary CGI-S-ADP: 60mg change -1.3 vs -0.9, effect size 0.37, p=0.0077 (nominal).","30mg dose minimal improvement; company to amend Phase 3 to remove 30mg arm.","Safety favorable: no QT signal, no deaths, no motor/cognition negative impact; AE rates similar to placebo.","Plan to continue Phase 3; detailed results at CTAD Nov 16-19, 2026 in Boston."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-401157","json":"https://secwatch.observer/filing/0001193125-26-401157.json","markdown":"https://secwatch.observer/filing/0001193125-26-401157.md","text":"https://secwatch.observer/filing/0001193125-26-401157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000119312526401157/0001193125-26-401157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000119312526401157/d168737d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-24T21:12:06.441903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}